|
Serious (Total = 94)
|
|
Methotrexate-Leflunomide (6.4)
|
Leflunomide increases toxicity of methotrexate by pharmacodynamic synergism.
|
|
Meloxicam-Methotrexate (5.3)
|
Meloxicam increases levels of methotrexate by decreasing renal clearance.
|
|
Clopidogrel-Omeprazole (5.3)
|
Omeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism.
|
|
Clopidogrel-Esomeprazole (5.3)
|
Esomeprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism.
|
|
Atorvastatin-Vitamin B3 (5.3)
|
Either increases toxicity of the other by pharmacodynamic synergism.
|
|
Atorvastatin-Fenofibrate (5.3)
|
Either increases effects of the other by pharmacodynamic synergism.
|
|
Significant (Total = 1017)
|
|
Aspirin-Losartan (5.5)
|
Aspirin decreases effects of losartan by pharmacodynamic antagonism. losartan and aspirin both increase serum potassium.
|
|
Losartan-Frusemide (3.2)
|
Losartan increases and furosemide decreases serum potassium.
|
|
Aspirin-Clopidogrel (3.0)
|
Either increases toxicity of the other by pharmacodynamic synergism.
|
|
Clopidogrel-Pantoprazole (2.3)
|
Pantoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism.
|
|
Celecoxib-Diclofenac sodium (2.0)
|
Celecoxib and diclofenac both increase anticoagulation and serum potassium.
|
|
Aspirin-Frusemide (2.0)
|
Aspirin increases and furosemide decreases serum potassium.
|
|
Minor (Total = 265)
|
|
Glipizide - Sitagliptin (7.6)
|
Either increases effects of the other by pharmacodynamic synergism.
|
|
Metformin - Vitamin B12 (5.7)
|
Metformin decreases levels of cyanocobalamin by unspecified interaction mechanism.
|
|
Metformin-Frusemide (3.8)
|
Metformin decreases levels of furosemide by unspecified interaction mechanism. Furosemide increases levels of metformin by unspecified interaction mechanism.
|
|
Methotrexate - Folic acid (3.4)
|
Folic acid decreases effects of methotrexate by pharmacodynamic antagonism.
|
|
Aspirin-Diltiazem (2.6)
|
Diltiazem increases effects of aspirin by unknown mechanism.
|
|
Metformin-Hydrochlorothiazide (2.6)
|
Hydrochlorothiazide will increase the level or effect of metformin by basic (cationic) drug competition for renal tubular clearance. Hydrochlorothiazide decreases effects of metformin by pharmacodynamic antagonism.
|
